Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Improved Sanofi HIV test approved in US:

This article was originally published in Clinica

Executive Summary

Sanofi Diagnostics Pasteur has received FDA approval for a more sensitive and specific version of its HIV-1/HIV-2 Peptide enzyme immunoassay. The broad reactivity of the test is achieved by combining the most immunodominant synthetic peptide epitopes derived from the env and pol gene products for both HIV-1 and HIV-2, according to the company. Sanofi's US subsidiary, Genetic Systems, developed the new test and is marketing the product to US blood banks and other institutions.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT085764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel